Cancer AI systems: We need oncologists to help us build trusted models

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

I recently attended a dinner party where guests lamented the use of generative AI in schools. They asked questions like, “Will kids stop learning and plug all their essay prompts into ChatGPT?”

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Bernard Chien
Chief product officer, COTA
Table of Contents

YOU MAY BE INTERESTED IN

A group of investigators led by Cedars-Sinai have developed and successfully tested a new artificial intelligence method to make launching cancer clinical trials easier and faster. The method uses patients’ pathology reports to automate the classification of patients by the severity of their cancers, potentially shortening the process of selecting candidates for clinical trials.

For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk.  By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...

An international, multidisciplinary team of leading neuro-oncology researchers and clinicians has released new recommendations for good clinical practice—a set of guidelines that helps ensure clinical trial results are reliable, and patients are protected—regarding the use of artificial intelligence methods to more accurately diagnose, monitor, and treat brain cancer patients. The team recently published two companion...

Bernard Chien
Chief product officer, COTA

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login